Company intelligence / Profile preview

MagForce

Ownership: Private
Employees: ~40
Development stage: Other

Overview

MagForce has developed and commercialized the first EU-approved nanotechnology-based medical device for treating solid brain tumors using magnetic hyperthermia. The company’s proprietary NanoTherm therapy involves injecting superparamagnetic iron oxide nanoparticles into a tumor and heating them with an alternating magnetic field to destroy or sensitize tumor cells. Over 100 patients have been treated in Europe; clinical studies are ongoing in the US for prostate cancer. Clinical adoption has been slow but supported by strong IP and strategic investment from Mithril Capital Management.

Therapeutic areas: Oncology
Modalities: DeviceNanoparticle (specifically superparamagnetic iron oxide nanoparticles)Non-pharmacological therapy (magnetic hyperthermia)
Industry: Therapeutic Medical Devices

Partnerships

Mithril Capital Management (strategic investor/partner in US subsidiary)

Beyond the preview

Go deeper on MagForce.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MagForce.